Bradenton Research Center

Bradenton, Florida 34250

2 studies enrolling now · 34 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease, Behavioral Variant Frontotemporal Dementia, Brain Infarction, Cerebral Ischemia, Chronic Uncontrolled Gout, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Early Alzheimer's Disease

Studies at this site

• A Study of Dotinurad Versus Allopurinol in Tophaceous Gout — Recruiting now
• A Study of Dotinurad Versus Allopurinol in Participants With Gout — Recruiting now
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis — Running, not enrolling
• A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Running, not enrolling
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
• A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) — Running, not enrolling
• Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate — Completed
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis — Completed
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) — Stopped early
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease — Completed
• A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia — Completed
• Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures — Completed
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures — Completed
• Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) — Stopped early
• Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy — Completed
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease — Stopped early
• Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures — Stopped early
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease — Completed
• Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy — Completed
• Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy — Completed
• A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak — Withdrawn before enrolling
• EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
• ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke — Stopped early
• A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil — Stopped early
• Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease — Stopped early